IC-MPGN: Clinical Trials

1 trial for IC-MPGN, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed. 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 31Completed 1

Follow IC-MPGN: new trials by email Literature Review of IC-MPGN trials Research Report on IC-MPGN

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Pegcetacoplan, Placebo - C3G, IC-MPGN
Phase 3CompletedApellis Pharmaceuticals, Inc.1242021-11-122026-01-29

Narrower conditions

Glomerulonephritis, Membranoproliferative (1)

Broader conditions

Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Glomerulonephritis (1)  ·  Immune System Diseases (1)  ·  Kidney Diseases (1)  ·  Male Urogenital Diseases (1)  ·  Nephritis (1)  ·  Urogenital Diseases (1)  ·  Urologic Diseases (1)

Interventions

pegcetacoplan (1)

Sponsors

Apellis Pharmaceuticals, Inc. (1)

Countries

Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Poland (1)  ·  South Korea (1)

Results publications

PMID 41337715, PMID 42133432